cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aerovate Therapeutics Inc
1 own
1 watching
Current Price
$20.57
$-1.34
(-6.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
670.28M
52-Week High
52-Week High
32.41500
52-Week Low
52-Week Low
9.41000
Average Volume
Average Volume
0.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization670.28M
icon52-Week High32.41500
icon52-Week Low9.41000
iconAverage Volume0.14M
iconDividend Yield--
iconP/E Ratio--
What does the Aerovate Therapeutics Inc do?
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Aerovate Therapeutics Inc make?
News & Events about Aerovate Therapeutics Inc.
Ticker Report
1 year ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Hunter Gillies sold 4,000 shares of Aerovate Therapeutics stock in a transaction that occurred on Friday, April 21st. The stock was sold at an average price of $19.50, for a total transaction of $78,000.00. Following the ...
Zolmax
1 year ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of the companys stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $19.39, for a total value of $290,850.00. The transaction was disclosed in a document filed with the ...
Globe Newswire
1 year ago
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced that Company management will ...
Zolmax
1 year ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of Aerovate Therapeutics stock in a transaction on Wednesday, February 1st. The stock was sold at an average price of $22.68, for a total transaction of $340,200.00. The sale was disclosed in a legal filing ...
Globe Newswire
1 year ago
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as ...
Frequently Asked Questions
Frequently Asked Questions
What is Aerovate Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aerovate Therapeutics Inc shares?
plus_minus_icon
How can I buy Aerovate Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aerovate Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aerovate Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aerovate Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aerovate Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aerovate Therapeutics Inc?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$20.57
$-1.34
(-6.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00